Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 04 05 2020
revised: 11 06 2020
accepted: 13 06 2020
entrez: 8 7 2020
pubmed: 8 7 2020
medline: 2 6 2021
Statut: ppublish

Résumé

Misfolding and aggregation of immunoglobulin light chains (LCs) leads to the degeneration of post-mitotic tissue in the disease immunoglobulin LC amyloidosis (AL). We previously reported the discovery of small molecule kinetic stabilizers of the native dimeric structure of full-length LCs, which slow or stop the LC aggregation cascade at the outset. A predominant structural category of kinetic stabilizers emerging from the high-throughput screen are coumarins substituted at the 7-position, which bind at the interface between the two variable domains of the light chain dimer. Here, we report the binding mode of another, more polar, LC kinetic stabilizer chemotype, 3,5-substituted hydantoins. Computational docking, solution nuclear magnetic resonance experiments, and x-ray crystallography show that the aromatic substructure emerging from the hydantoin 3-position occupies the same LC binding site as the coumarin ring. Notably, the hydantoin ring extends beyond the binding site mapped out by the coumarin hits. The hydantoin ring makes hydrogen bonds with both LC monomers simultaneously. The alkyl substructure at the hydantoin 5-position partially occupies a novel binding pocket proximal to the pocket occupied by the coumarin substructure. Overall, the hydantoin structural data suggest that a larger area of the LC variable-domain-variable-domain dimer interface is amenable to small molecule binding than previously demonstrated, which should facilitate development of more potent full-length LC kinetic stabilizers.

Identifiants

pubmed: 32631553
pii: S0960-894X(20)30467-4
doi: 10.1016/j.bmcl.2020.127356
pmc: PMC7402200
mid: NIHMS1608908
pii:
doi:

Substances chimiques

Hydantoins 0
Immunoglobulin Light Chains 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

127356

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124169
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK046335
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM069832
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Biophys Chem. 2015 Dec;207:13-20
pubmed: 26263488
Amyloid. 2009 Mar;16(1):1-8
pubmed: 19291508
J Clin Oncol. 2012 Dec 20;30(36):4541-9
pubmed: 23091105
Nat Rev Drug Discov. 2015 Nov;14(11):759-80
pubmed: 26338154
Nat Protoc. 2016 May;11(5):905-19
pubmed: 27077332
Curr Top Med Chem. 2012;12(22):2523-33
pubmed: 23339305
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8360-8369
pubmed: 30971495
J Biol Chem. 2014 Oct 3;289(40):27513-25
pubmed: 25138218
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):854-863
pubmed: 30598439
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34
pubmed: 22645360
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Nat Rev Dis Primers. 2018 Oct 25;4(1):38
pubmed: 30361521
Elife. 2015 Nov 18;4:e10935
pubmed: 26576950
Biochemistry. 1999 Oct 19;38(42):14101-8
pubmed: 10529258
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Science. 2003 Jan 31;299(5607):713-6
pubmed: 12560553
Amyloid. 1999 Sep;6(3):165-71
pubmed: 10524280
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Mol Cell Proteomics. 2008 Aug;7(8):1570-83
pubmed: 18474516
J Mol Biol. 2016 Oct 23;428(21):4280-4297
pubmed: 27569045
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5446-50
pubmed: 8202506
PLoS One. 2013 Sep 27;8(9):e76022
pubmed: 24086679

Auteurs

Nicholas L Yan (NL)

Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.

Diogo Santos-Martins (D)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Enrico Rennella (E)

Departments of Molecular Genetics, Biochemistry and Chemistry, The University of Toronto, Toronto, ON M5S1A8, Canada.

Brittany B Sanchez (BB)

Automated Synthesis Facility, The Scripps Research Institute, La Jolla, CA 92037, USA.

Jason S Chen (JS)

Automated Synthesis Facility, The Scripps Research Institute, La Jolla, CA 92037, USA.

Lewis E Kay (LE)

Departments of Molecular Genetics, Biochemistry and Chemistry, The University of Toronto, Toronto, ON M5S1A8, Canada; The Hospital for Sick Children, Program in Molecular Medicine, 555 University Avenue, Toronto, ON M5G1X8, Canada.

Ian A Wilson (IA)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Gareth J Morgan (GJ)

Section of Hematology and Medical Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; The Amyloidosis Center, Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: gjmorgan@bu.edu.

Stefano Forli (S)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: forli@scripps.edu.

Jeffery W Kelly (JW)

Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: jkelly@scripps.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH